K

    Kura Oncology Inc (KURA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $12.65
    -0.01 (-0.08%)

    Market Cap: $1.13B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    70%(28/40)
    Avg Surprise
    -14.06%
    Streak
    2 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.80
    Range$-0.99 - $-0.70
    9 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.93-16.4%
    60d ago$-0.90-13.3%
    30d ago$-0.89-12.1%
    7d ago$-0.81-1.4%
    Current$-0.80
    Revenue Consensus
    $24M
    Range$9M - $29M
    13 analysts
    Dec 31, 2026
    EPS Consensus$-0.74
    Range$-1.03 - $-0.53
    8 analysts
    Revenue Consensus
    $28M
    Range$8M - $70M
    14 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.74---
    Sep 26EST
    		-$-0.80---
    Jun 26
    		$-0.77$-0.89+13.48%Beat-2.7%
    Mar 26
    		$-0.83$-0.90+8.35%Beat-25.4%
    Dec 25
    		$-0.92$-0.49-87.76%Miss-318.2%
    Sep 25
    		$-0.85$-0.68-25.00%Miss-34.9%
    Jun 25
    		$-0.75$0.15-600.00%Miss-27.1%
    Mar 25
    		$-0.66$-0.60-10.00%Miss-11.9%
    Dec 24
    		$-0.22N/A+65.49%Beat+60.0%
    Sep 24
    		$-0.63$-0.61-3.28%Miss-26.0%
    Jun 24
    		$-0.59$-0.62+4.84%Beat-11.3%
    Mar 24
    		$-0.59$-0.54-9.26%Miss-18.0%
    Dec 23
    		$-0.55$-0.55+0.00%Beat-12.2%
    Sep 23
    		$-0.50$-0.55+9.09%Beat+5.7%
    Jun 23
    		$-0.53$-0.56+5.36%Beat-1.9%
    Mar 23
    		$-0.50$-0.54+7.41%Beat-2.0%
    Dec 22
    		$-0.49$-0.57+14.04%Beat+0.0%
    Sep 22
    		$-0.53$-0.56+5.36%Beat-6.0%
    Jun 22
    		$-0.52$-0.52+0.00%Beat-2.0%
    Mar 22
    		$-0.49$-0.52+5.77%Beat-6.5%
    Dec 21
    		$-0.49$-0.53+7.55%Beat-8.9%
    Sep 21
    		$-0.50$-0.54+7.41%Beat-19.0%
    Jun 21
    		$-0.51$-0.50-2.00%Miss-27.5%
    Mar 21
    		$-0.46$-0.42-9.52%Miss-9.5%
    Dec 20
    		$-0.45$-0.45+0.00%Beat-15.4%
    Sep 20
    		$-0.42$-0.40-5.00%Miss-16.7%
    Jun 20
    		$-0.40$-0.43+6.98%Beat-5.3%
    Mar 20
    		$-0.42$-0.42+0.00%Beat-13.5%
    Dec 19
    		$-0.39$-0.41+4.88%Beat+7.1%
    Sep 19
    		$-0.36$-0.39+7.69%Beat+10.0%
    Jun 19
    		$-0.38$-0.41+7.32%Beat+15.6%
    Mar 19
    		$-0.37$-0.44+15.91%Beat+19.6%
    Dec 18
    		$-0.42$-0.42+0.00%Beat-13.5%
    Sep 18
    		$-0.40$-0.43+6.98%Beat-5.3%
    Jun 18
    		$-0.45$-0.43-4.65%Miss-12.5%
    Mar 18
    		$-0.46$-0.35-31.43%Miss-17.9%
    Dec 17
    		$-0.37$-0.36-2.78%Miss+2.6%
    Sep 17
    		$-0.38$-0.38+0.00%Beat-2.7%
    Jun 17
    		$-0.40$-0.43+6.98%Beat-
    Mar 17
    		$-0.39$-0.42+7.14%Beat-
    Dec 16
    		$-0.38$-0.40+5.00%Beat-
    Sep 16
    		$-0.37$-0.39+5.13%Beat-

    Key Metrics

    Valuation
    P/E Ratio-3.76EV/EBITDA-2.48x
    Price/FCF-9.57xFCF Yield-10.45%
    Profitability
    Profit Margin0.00%Operating Margin-349.80%
    ROE-167.70%ROIC-546.35%
    Financial Health
    Debt/Equity0.20xInterest Coverage-224.01x
    Current Ratio4.73xQuick Ratio4.71x
    Trading Statistics
    Beta0.38Avg Volume2.21M
    52-Week High$13.9052-Week Low$7.36

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$12.60
    SMA 20$11.27
    SMA 50$10.89
    SMA 200$9.76
    EMA 10$12.39
    EMA 20$11.73
    EMA 50$10.91
    EMA 200$9.72

    MACD

    Line: 0.75Signal: 0.58Hist: 0.17

    ADX

    ADX: 32.7+DI: 32.8-DI: 14.9

    Aroon & PSAR

    Aroon Up84.0
    Aroon Down20.0
    PSAR$13.90

    Bollinger Bands

    Upper Band$14.25
    Lower Band$8.29
    %B Position5285%(Upper)
    Band Width0.73

    RSI (14-Day)

    Neutral
    61.9

    Momentum Oscillators

    Stoch %K74.7
    Stoch %D79.9
    Williams %R-30.3
    ROC (10d)12.1%
    Momentum1.37
    CCI (20d)66.8
    MFI (14d)65.2

    Volatility Measures

    ATR (14d)$0.69(5.5%)
    StdDev (20d)1.49
    Hist Vol66.3%(High)

    Volume Flow

    VWAP$12.64
    OBV62.6M
    AD Line-17.2M
    CMF (20d)-0.101

    Volume Metrics

    Avg Vol (20d)2.3M
    Vol Ratio0.9x
    VWMA (20d)$11.78

    Pivot Points

    R3$13.58
    R2$13.37
    R1$13.02
    Pivot Point$12.81
    S1$12.46
    S2$12.25
    S3$11.90

    Advanced Oscillators

    TSI28.65
    Ultimate Osc52.0
    KST208.94

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$20.87M$18.27M$17.34M$20.75M$15.29M$14.11M$53.88M$0$0$0$1.27M$0
    Cost of Revenue$243,000$262,000$57,000$0$0$0$204,000$0$0$0$214,000$0
    Gross Profit$20.63M$18.00M$17.28M$20.75M$15.29M$14.11M$53.88M$0$0$0$-214,000$0
    Operating Expenses$93.64M$96.82M$103.55M$100.75M$87.95M$78.81M$76.34M$59.88M$56.40M$54.45M$46.76M$42.47M
    R&D$61.89M$65.26M$64.41M$67.91M$62.78M$55.97M$52.27M$41.70M$39.73M$36.27M$32.53M$29.33M
    SG&A$31.75M$31.55M$39.14M$32.84M$25.17M$22.84M$24.07M$18.18M$16.68M$18.18M$14.23M$13.14M
    Operating Income$-73,010,000$-78,815,000$-86,268,000$-79,997,000$-72,666,000$-64,700,000$-22,455,000$-59,884,000$-56,404,000$-54,452,000$-46,762,000$-42,473,000
    Interest Income$5.03M$5.83M$5.69M$6.27M$6.93M$7.88M$5.66M$5.89M$5.97M$5.33M$4.37M$4.28M
    Interest Expense$345,000$336,000$346,000$393,000$391,000$382,000$403,000$412,000$406,000$398,000$394,000$404,000
    Income Before Tax$-68,322,000$-73,325,000$-80,928,000$-74,116,000$-66,122,000$-57,203,000$-17,199,000$-54,404,000$-50,837,000$-49,525,000$-42,786,000$-38,602,000
    Income Tax Expense$5,000$8,000$71,000$0$0$226,000$2.02M$0$0$0$0$0
    Net Income$-68,327,000$-73,333,000$-80,999,000$-74,116,000$-66,122,000$-57,429,000$-19,217,000$-54,404,000$-50,837,000$-49,525,000$-42,786,000$-38,602,000
    EBITDA$-73,271,000$-79,254,000$-87,144,000$-81,616,000$-74,824,000$-66,988,000$-24,996,000$-62,979,000$-59,624,000$-57,366,000$-49,162,000$-45,025,000
    EBIT$-73,010,000$-78,815,000$-86,268,000$-79,997,000$-72,666,000$-64,700,000$-22,455,000$-59,884,000$-56,404,000$-54,452,000$-46,762,000$-42,473,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about KURA

    News

    The $1.24 Billion Reason Why Kura Oncology Stock Is Up Today

    Kura Oncology (KURA) stock rallied significantly after CEO Troy Wilson made a substantial insider purchase of 100,000 shares for $1.24 million, adding to a previous $1.11 million investment. This insider buying signals confidence in the biotech firm, especially as its share price has already seen a strong increase. The company's stock performance is also supported by the commercial success of its FDA-approved treatment, KOMZIFTI, and expectations of future collaboration payments and positive trial results.

    Barchart.com•8/25/26•
    Neutral

    Kura Oncology Shares Rise After CEO Purchases 100,000 Shares

    Kura Oncology's stock increased following its CEO's purchase of 100,000 shares. The company, a clinical-stage biopharmaceutical firm, focuses on precision medicine for cancer treatment with several small molecule product candidates in its pipeline. Analysts currently have a "BUY" consensus rating on Kura Oncology, with an average target price significantly above its last closing price.

    www.marketscreener.com•8/25/26•
    Bullish

    Kura Oncology Shares Surge 9% Following CEO’s $2.35 Million Purchase Over Eight Days

    Kura Oncology's shares surged by 8.87% after CEO Troy Wilson acquired 200,000 shares for $2.351 million over eight days, creating an unrealized profit of $349,000. This insider confidence is bolstered by strong growth in Kura's debut product, KOMZIFTI, which saw a 57% sequential increase in net product revenue. Despite a net loss, the company maintains a robust balance sheet with $519 million in cash, supporting its ziftomenib program.

    TechStock²•8/25/26•
    Bullish

    Kura Oncology Shares Jump After CEO Buys $1.24 Million of Stock

    Kura Oncology Inc. (NASDAQ:KURA) shares surged by 11.0% in pre-market trading after its President and CEO, Troy Edward Wilson, purchased 100,000 shares worth $1.24 million. This significant insider buying, executed at a weighted average price of $12.39 per share, increased Wilson's indirect ownership and is seen by investors as a strong signal of confidence in the biotechnology company's future prospects.

    Yahoo Finance•8/25/26•
    Bullish

    Kura Oncology stock jumps after CEO buys $1.24M in shares

    Kura Oncology Inc. (NASDAQ:KURA) shares rose 11.0% in premarket trading after President and CEO Troy Edward Wilson purchased $1.24 million worth of company stock. Wilson acquired 100,000 shares at a weighted average price of $12.39, significantly increasing his indirect and direct holdings. This insider purchase is often seen as a signal of management's confidence in the company's future prospects.

    Investing.com•8/25/26•
    Bullish

    Frequently Asked Questions About KURA

    Does KURA pay dividends?
    Kura Oncology Inc (KURA) does not currently pay a regular dividend.
    What is KURA's market cap?
    Kura Oncology Inc (KURA) has a market capitalization of $1.13B with a current stock price of $12.65.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In